Emergent BioSolutions gets gov't order for BioThrax

Emergent BioSolutions could earn up to $1.25 billion over the next 5 years for providing 44.8 million doses of its BioThrax anthrax vaccine to the U.S. government. The developer revealed in May the government was contemplating the contract. Report

Suggested Articles

GSK's Shingrix supply has recovered after COVID-19 prompted a slowdown in vaccinations.

To eradicate SARS-CoV-2, we'll need a vaccine that's 70% effective—and 70% of the population will need to receive it, an FDA official says.

The U.K. government, fearing losing the supply race, agreed to buy 60 million doses of GSK-Sanofi's COVID-19 vaccine even before phase 1.